t
On 1 August 2022, Nuformix plc announced the posting of its Annual Financial Report for the year ended 31 March 2022 and the 2022 Notice of Annual General Meeting to its shareholders. The Annual General Meeting is scheduled for 25 August 2022 at 2.00 pm.
| Date | 1 Aug 2022 |
| Time | 12:13:09 |
| Category | AGMs and other meetings |
| ID | 4720U |
1 August 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Posting of Annual Report and Notice of AGM
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 31 March 2022 (the "Annual Financial Report 2022") and the 2022 Notice of Annual General Meeting ("AGM") are today being posted to its shareholders:
A full pdf version of the Annual Financial Report 2022 together with the Notice of Annual General Meeting is available for download from the Investor Information section on the Company's website www.nuformix.com.
The Annual Financial Report 2022 will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.
The Annual General Meeting will be held on 25 August 2022 at 2.00 pm at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
|
Nuformix plc |
|
|
Dr Julian Gilbert, Non-executive Chairman
|
Via IFC Advisory
|
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
John Howes (Corporate Broking) |
+44 (0) 20 3650 3652
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.